Promising Future for Amylyx Pharmaceuticals: Buy Rating Backed by Avexitide’s Market Potential

TD Cowen analyst Joseph Thome has maintained their bullish stance on AMLX stock, giving a Buy rating on July 23.

Joseph Thome has given his Buy rating due to a combination of factors related to Amylyx Pharmaceuticals Inc’s promising future prospects. The company is progressing well with its Phase III LUCIDITY study for avexitide, which is expected to complete enrollment by 2025 and deliver initial data in the first half of 2026. The potential market for avexitide is significant, as it could become the first FDA-approved treatment for post-bariatric hypoglycemia (PBH), a condition affecting a substantial number of bariatric surgery patients.
Thome notes that the market opportunity for avexitide could be substantial, with estimates suggesting that the therapy could generate peak U.S. sales of $1.5 billion. This projection is based on conservative assumptions about patient penetration and pricing, with the potential for even greater market uptake. The lack of existing standard care for PBH and the challenges in diagnosing the condition further underscore the potential demand for avexitide, making Amylyx’s stock an attractive investment opportunity.

In another report released on July 23, Bank of America Securities also reiterated a Buy rating on the stock with a $10.00 price target.